technology and innovation firm
investing in behavioral health,
mental health, autism, and
complex chronic conditions,
the most common of which
affect 1 in 4 individuals and
collectively represent a
$1T+ market.
disorders is achievable with a
simple blood test.
therapeutics exist to improve
nervous system function.
core symptoms of neurological
conditions.
is affordable and tech-enabled.
are manageable through
precision nutrition.
for neurodiverse individuals
are plentiful.
is comprehensive, outcomes-
based, and led by doctors.
is zero.
detect and treat core ASD
symptoms.
is automated and efficient.
for autism and related conditions.
and affordable, regardless of your
insurer.
of youth are supported across
multiple disciplines.
is tech-enabled and seamless.
with special healthcare needs.
disabilities is accessible.
validated and data-driven.
primary care is available
wherever you are.
Seed, 2021
diagnosis for
neurodevelopmental
disorders is achievable
with a simple blood test.
AIF is building a world where
September, 2021
behavioral intervention
is clinically validated
and data-driven.
AIF is building a world where
Series C, 2021
microbiome-targeted
therapeutics exist to
improve nervous
system function.
AIF is building a world where
Seed, 2021
care for individuals with
disabilities is accessible.
AIF is building a world where
Series A, 2021
treatments are safe,
effective, and well-tolerated.
AIF is building a world where
Seed, 2021
therapy for behavioral
conditions is affordable
and tech-enabled.
AIF is building a world where
Bridge, 2021
chronic health
conditions are manageable
through precision nutrition.
AIF is building a world where
Growth, 2021
employment opportunities
for neurodiverse individuals
are plentiful.
AIF is building a world where
Strategic, 2022
care for neurological
conditions is comprehensive,
outcomes-based, and
led by doctors.
AIF is building a world where
Bridge, 2022
wait times for ASD
diagnoses is zero.
AIF is building a world where
Seed, 2022
precision medicine tools
exist to detect and treat
core ASD symptoms.
AIF is building a world where
Series A, 2024
behavioral health
infrastructure is automated
and efficient.
AIF is building a world where
Series A, 2024
safe, effective therapeutics
exist for autism and related
conditions.
AIF is building a world where
Series A, 2025
behavioral health
is accessible and afforable,
regardless of your insurer.
AIF is building a world where
Growth, 2025
the special education needs of
youth are supported
across multiple disciplines.
AIF is building a world where
AS SEEN ON
technology and innovation firm
investing in behavioral health,
mental health, autism, and
complex chronic conditions,
the most common of which
affect 1 in 4 individuals and
collectively represent a
$1T+ market.
disorders is achievable with a
simple blood test.
therapeutics exist to improve
nervous system function.
core symptoms of neurological
conditions.
is affordable and tech-enabled.
are manageable through
precision nutrition.
for neurodiverse individuals
are plentiful.
is comprehensive, outcomes-
based, and led by doctors.
is zero.
detect and treat core ASD
symptoms.
is automated and efficient.
for autism and related conditions.
and affordable, regardless of your
insurer.
of youth are supported across
multiple disciplines.
is tech-enabled and seamless.
with special healthcare needs.
disabilities is accessible.
validated and data-driven.
primary care is available
wherever you are.
